Edward Tenthoff

Osiris Rises on European Stem-Cell Drug Title Decision

Osiris Therapeutics Inc. rose the most in eight months after European regulators transferred the orphan drug title for a stem cell therapy to the company, making it easier to seek a buyer or partner for the treatment.

Regeneron Says FDA Delays Eylea Drug for Blindness

Regeneron Pharmaceuticals Inc. declined as much as 13 percent in extended trading after U.S. regulators delayed a decision on whether to approve the company’s treatment for a common cause of blindness.

Sarepta Rises on Muscular Dystrophy Results: Boston Mover

Sarepta Therapeutics Inc. tripled in trading after its drug for Duchenne muscular dystrophy helped patients walk farther in a study and restored a key protein lacking in some of those with the disease.

Arena’s Diet Pill May Spur Renewed Race From Drugmakers

Arena Pharmaceuticals Inc.’s weight- loss pill, the first cleared in the U.S. in 13 years, and an expected rival are potential breakthroughs in the treatment of obesity that may spur major drugmakers into the market.

First Weight-Loss Drug Approved in 13 Years Spurs Eisai

Eisai Co. surged the most in two years in Tokyo trading after its partner won Food and Drug Administration approval for a weight-loss pill, making it the first obesity medication cleared for the U.S. in 13 years.

First Diet Pill in Decade Turns Arena Into Deal Bait: Real M&A

The first medication in more than a decade to help 78 million obese Americans slim down is turning into takeover bait.

Idenix Leads Hepatitis Drug Developers Higher on Inhibitex

Idenix Pharmaceuticals Inc. and Achillion Pharmaceuticals Inc., developers of hepatitis C drugs, rose on speculation they may follow Inhibitex Inc. and Pharmasset Inc. as acquisition targets.

Exelixis Shares Fall Most Ever on Prostate Drug Study Rules

Exelixis Inc., a biotechnology company with no approved products, plunged the most in 11 years after failing to agree with U.S. regulators on special rules for a study of its experimental prostate cancer drug.

Micromet's Cancer Missiles Lure Boehringer, Sanofi

Micromet Inc. , a 17-year-old biotechnology company with no medicines on the market, is attracting attention from product-hungry drugmakers. The lure: a technology for fighting cancer without using toxic chemicals.

Osiris Shares Increase on Approval for Stem-Cell Therapy

Osiris Therapeutics Inc. rose after the company said it won the world’s first approval for a stem- cell drug, gaining clearance in Canada to sell Prochymal for a disease that can attack patients who received bone-marrow transplants.

"They've started to get approvals for Prochymal."

- Edward Tenthoff on Feb 19, 2013

New York

San Francisco

Europe

New Jersey

Nadal Beats Ferrer to Win Historic Eighth French Title

UN Mission in Libya Urges Restraint as Benghazi Clashes Kill 31

German Towns on Elbe Fight Floods as Water Rolls North

Hawke Horror Flick ‘The Purge’ Outsells Vaughn-Wilson Flop

Privacy Protection Urged After U.S. Surveillance Revealed